Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Dutch Ministry of Economic Affairs, Agriculture and Innovation (Agentschap NL) has given loan of EUR1.2m to to-BBB to support the planned Phase I/II study in brain cancer.
Subscribe to our email newsletter
to-BBB is planning to initiate the Phase I/II clinical trial in a few months at three academic hospitals in the Netherlands led by neuro-oncology experts of the Antoni van Leeuwenhoek hospital (AVL-NKI).
Based on the company’s proprietary G-Technology, to-BBB is developing its lead compound 2B3-101, brain-targeted doxorubicin liposomes.
2B3-101 has shown reduction of brain tumor growth in proof-of-concept studies at the Netherlands Cancer Institute.
to-BBB CEO Willem van Weperen said their brain cancer lead program will address the high medical need of patients with brain cancer, while also establishing the brain delivery platform in humans.